Geopolitical tensions and emerging threats from technologies are forcing businesses to rethink how they address risk ...
SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861) 1, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback